Insight Genetics Establishes Operations at CET Life Sciences Center

    NASHVILLE, Tenn., Dec. 4 /PRNewswire/ -- Cumberland Emerging
 Technologies, Inc. (CET) (http://www.cet-fund.com/) today announced that
 Insight Genetics, Inc. has secured lab and office space at the CET Life
 Sciences Center in downtown Nashville, which is adjacent to the Union
 Station Hotel.
 
     A spin-off of Nashville-based Genetic Assays, Inc., Insight Genetics
 was formed in January 2007 to improve the quality, safety and efficiency of
 disease diagnosis and treatment and make a new level of targeted drug
 therapy possible. The company has created a patented, highly specific
 genetic screening technology -- Template Exchange Extension Reaction
 (TEER(TM)) -- that will be a powerful tool in the emerging personalized
 medicine market.
 
     Insight Genetics is exploring initial commercial applications for its
 TEER technology within cancer drug rescue, discovery and development, as
 well as early cancer detection and monitoring. The company is currently
 seeking partnerships that will accelerate the commercialization of TEER.
 
     "CET is an excellent partner for early-stage and emerging bioscience
 companies," said Eric Dahlhauser, chief executive officer of Insight
 Genetics. "The support, expertise and resources CET provides companies like
 ours are unmatched in this region and the Life Sciences Center in downtown
 Nashville provides a great, central site for Insight Genetics as we grow."
 
     The CET Life Sciences Center provides lab and office space, equipment
 and infrastructure support to several tenants, including the Tennessee
 Biotechnology Association, which has established its headquarters at the
 center.
 
     "We are very pleased to welcome Insight Genetics to the Life Sciences
 Center," said A.J. Kazimi, chief executive officer of CET and Cumberland
 Pharmaceuticals Inc. "Their exciting new technology holds great promise for
 patient care, and we look forward to helping them grow through the start-up
 phase and on to commercial viability."
 
     About CET
 
     Cumberland Emerging Technologies, Inc. (www.cet-fund.com) is a joint
 initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University
 and the Tennessee Technology Development Corporation. The mission of CET is
 to bring biomedical technologies and products conceived at Vanderbilt and
 other regional research centers to the marketplace. CET helps manage the
 development and commercialization process for select projects, and provides
 expertise on intellectual property, regulatory, manufacturing and marketing
 issues that are critical to successful new biomedical products. CET's Life
 Sciences Center, located in Nashville, Tennessee, provides laboratory
 space, equipment and infrastructure to early-stage life sciences companies.
 
 
 

SOURCE Cumberland Emerging Technologies, Inc.